FORM 3
        
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      
1. Name and Address of Reporting Person * Louie Linda H. 2. Date of Event Requiring Statement (MM/DD/YYYY)
7/23/2020 

3. Issuer Name and Ticker or Trading Symbol AMGEN INC [AMGN]
(Last)       (First)       (Middle)
ONE AMGEN CENTER DRIVE
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)_____ Director                          _____ 10% Owner
___X___ Officer (give title below)        _____ Other (specify below)
VP, Finance & CAO /
(Street)
THOUSAND OAKS, CA 91320      
(City)             (State)             (Zip)
5. If Amendment, Date Original Filed(MM/DD/YYYY)
 

6. Individual or Joint/Group Filing(Check Applicable Line)_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)
2. Amount of Securities Beneficially Owned
(Instr. 4)
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock  6175 (1)(2) D   

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 4)
2. Date Exercisable and Expiration Date
(MM/DD/YYYY)
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Nqso (Right to Buy)  5/3/2018 (3) 5/3/2026  Common Stock  370  $156.35  D   
Nqso (Right to Buy)  5/1/2019 (4) 5/1/2027  Common Stock  1633  $162.60  D   
Nqso (Right to Buy)  4/27/2020 (5) 4/27/2028  Common Stock  1301  $177.46  D   
Nqso (Right to Buy)  5/3/2021 (6) 5/3/2029  Common Stock  1723  $177.31  D   
Nqso (Right to Buy)  5/5/2022 (7) 5/5/2030  Common Stock  1417  $236.36  D   

Explanation of Responses:
(1)  These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 63 RSUs which fully vest on 5/1/2021; 114 RSUs which vest in two installments of 56 on 4/27/2021 and 58 on 4/27/2022; 197 RSUs which vest in two installments of 65 on 5/3/2021 and 5/3/2022 and one installment of 67 on 5/3/2023; and 169 RSUs which vest in installments of 55 on 5/5/2022, 56 on 5/5/2023 and 58 on 5/5/2024. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.
(2)  These shares include 22 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.
(3)  370 non-qualified stock options have vested and are exercisable.
(4)  1,077 of these non-qualified stock options have vested and are exercisable and 556 of these options will vest and become exercisable on 5/1/2021.
(5)  429 of these non-qualified stock options have vested and are exercisable and the remaining options will vest and become exercisable in installments of 429 on 4/27/2021 and 443 on 4/27/2022.
(6)  These non-qualified stock options will vest and become exercisable in three installments of 568 on 5/3/2021, 569 on 5/3/2022 and 586 on 5/3/2023.
(7)  These non-qualified stock options will vest and become exercisable in three installments of 467 on 5/5/2022, 468 on 5/5/2023 and 482 on 5/5/2024.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Louie Linda H.
ONE AMGEN CENTER DRIVE
THOUSAND OAKS, CA 91320


VP, Finance & CAO

Signatures
/s/ Andrea A. Robinson, attorney-in-fact for Ms. Louie 7/29/2020
**Signature of Reporting Person Date
Amgen (NASDAQ:AMGN)
Historical Stock Chart
From Sep 2020 to Oct 2020 Click Here for more Amgen Charts.
Amgen (NASDAQ:AMGN)
Historical Stock Chart
From Oct 2019 to Oct 2020 Click Here for more Amgen Charts.